

Audit Review Table					
Presbyterian Health Plan, Inc. (Org ID: 579, Sub ID: 4104, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2023; Date & Timestamp - 6/14/2024 1:01:00 PM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		76.81%	R	R	Reported
Counseling for Nutrition (Total)		65.09%	R	R	Reported
Counseling for Physical Activity (Total)		64.34%	R	R	Reported
Childhood Immunization Status (CIS)					
DTaP		74.94%	R	R	Reported
IPV		87.83%	R	R	Reported
MMR		86.37%	R	R	Reported
HIB		86.86%	R	R	Reported
Hepatitis B		90.51%	R	R	Reported
VZV		85.64%	R	R	Reported
Pneumococcal Conjugate		77.13%	R	R	Reported
Hepatitis A		85.89%	R	R	Reported
Rotavirus		76.40%	R	R	Reported
Influenza		36.25%	R	R	Reported
Combo 3		72.75%	R	R	Reported
Combo 7		65.45%	R	R	Reported
Combo 10		31.63%	R	R	Reported
Immunizations for Adolescents (IMA)					
Meningococcal		83.60%	R	R	Reported
Tdap		85.15%	R	R	Reported
HPV		35.19%	R	R	Reported
Combination 1		82.94%	R	R	Reported
Combination 2		34.48%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		34.79%	R	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		44.61%	R	R	Reported
Colorectal Cancer Screening (COL)					
(Total)		31.21%	R	R	Reported
Chlamydia Screening in Women (CHL)					
(Total)		47.19%	R	R	Reported
Oral Evaluation, Dental Services (OED)					
	Y				
(0-2)		29.37%	R	R	Reported
(3-5)		60.20%	R	R	Reported
(6-14)		61.50%	R	R	Reported
(15-20)		41.45%	R	R	Reported
(Total)		51.84%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		7.02%	R	R	Reported
(3-4)		9.84%	R	R	Reported
(Total)		8.47%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)					
	Y				
(Total)		77.73%	R	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)					
Use of Spirometry Testing in the Assessment and Diagnosis of COPD		19.39%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)					
	Y				
Systemic Corticosteroid		57.16%	R	R	Reported
Bronchodilator		68.76%	R	R	Reported
Asthma Medication Ratio (AMR)					
	Y				
(Total)		70.77%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		41.52%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)					
	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack		50.00%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)					
	Y				
Received Statin Therapy (Total)		65.47%	R	R	Reported
Statin Adherence 80% (Total)		69.75%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Initiation (Total)		2.94%	R	R	Reported
Engagement1 (Total)		5.48%	R	R	Reported

<i>Engagement2 (Total)</i>		3.91%	R	R	Reported
<i>Achievement (Total)</i>		1.17%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes (HBD)					
<i>HbA1c Control (<8%)</i>		39.11%	R	R	Reported
<i>Poor HbA1c Control</i>		53.79%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
<i>Blood Pressure Control for Patients With Diabetes</i>		43.28%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
<i>Eye Exam for Patients With Diabetes</i>		47.86%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
<i>(Total)</i>		33.80%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
<i>Received Statin Therapy</i>		51.34%	R	R	Reported
<i>Statin Adherence 80%</i>		66.12%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
<i>(Total)</i>		26.86%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
<i>Effective Acute Phase Treatment</i>		68.35%	R	R	Reported
<i>Effective Continuation Phase Treatment</i>		51.14%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
<i>Initiation Phase</i>		33.30%	R	R	Reported
<i>Continuation and Maintenance Phase</i>		39.26%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
<i>30 days (Total)</i>		55.14%	R	R	Reported
<i>7 days (Total)</i>		36.11%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
<i>30 days (Total)</i>		51.04%	R	R	Reported
<i>7 days (Total)</i>		34.92%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
<i>Alcohol (Total)</i>		4.21%	R	R	Reported
<i>Opioid (Total)</i>		3.50%	R	R	Reported
<i>Other (Total)</i>		4.60%	R	R	Reported
<i>Any (Total)</i>		9.45%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				
<i>30 days (Total)</i>		42.46%	R	R	Reported
<i>7 Days (Total)</i>		22.33%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
<i>30 days (Total)</i>		31.45%	R	R	Reported
<i>7 days (Total)</i>		19.39%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
<i>(Total)</i>		12.60%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
<i>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications</i>		84.08%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
<i>Diabetes Monitoring for People With Diabetes and Schizophrenia</i>		66.54%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
<i>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia</i>		78.57%	NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
<i>Adherence to Antipsychotic Medications for Individuals With Schizophrenia</i>		56.84%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y				
<i>Blood Glucose Testing (Total)</i>		64.07%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		44.30%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		43.77%	R	R	Reported
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)					
<i>Non-Recommended Cervical Cancer Screening in Adolescent Females</i>		0.53%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
<i>(Total)</i>		84.37%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
<i>(Total)</i>		62.08%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					

	(Total)	71.85%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
	<i>Use of Opioids at High Dosage</i>	4.00%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
	<i>Multiple Prescribers</i>	15.18%	R	R	Reported
	<i>Multiple Pharmacies</i>	2.14%	R	R	Reported
	<i>Multiple Prescribers and Multiple Pharmacies</i>	0.89%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
	<i>>=15 Days (Total)</i>	5.22%	R	R	Reported
	<i>>=31 Days (Total)</i>	3.56%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
	(Total)	72.08%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
	<i>Initiation of SUD Treatment - Total (Total)</i>	54.22%	R	R	Reported
	<i>Engagement of SUD Treatment - Total (Total)</i>	21.48%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
	<i>Timeliness of Prenatal Care</i>	75.52%	R	R	Reported
	<i>Postpartum Care</i>	74.63%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
	(Total)	57.22%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
	<i>(First 15 Months)</i>	69.31%	R	R	Reported
	<i>(15 Months-30 Months)</i>	67.32%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
	(Total)	44.77%	R	R	Reported
Ambulatory Care (AMB)			R	R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPU)			R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
	(Total)	26.72%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			NR	NR	Not Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
	<i>DTaP</i>	72.21%	R	R	Reported
	<i>IPV</i>	86.52%	R	R	Reported
	<i>MMR</i>	86.32%	R	R	Reported
	<i>HiB</i>	85.58%	R	R	Reported
	<i>Hepatitis B</i>	87.36%	R	R	Reported
	<i>VZV</i>	85.91%	R	R	Reported
	<i>Pneumococcal Conjugate</i>	72.62%	R	R	Reported
	<i>Hepatitis A</i>	85.91%	R	R	Reported
	<i>Rotavirus</i>	72.71%	R	R	Reported
	<i>Influenza</i>	38.64%	R	R	Reported
	<i>Combo 3</i>	65.15%	R	R	Reported
	<i>Combo 7</i>	58.84%	R	R	Reported
	<i>Combo 10</i>	30.27%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
	<i>Meningococcal</i>	83.44%	R	R	Reported
	<i>Tdap</i>	85.11%	R	R	Reported
	<i>HPV</i>	35.19%	R	R	Reported
	<i>Combination 1</i>	82.79%	R	R	Reported
	<i>Combination 2</i>	34.45%	R	R	Reported
Breast Cancer Screening (BCS-E)					
	<i>Breast Cancer Screening</i>	40.39%	R	R	Reported
Cervical Cancer Screening (CCS-E)					
	<i>Cervical Cancer Screening</i>	43.23%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
	(Total)	30.66%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
	<i>Initiation Phase</i>	33.30%	R	R	Reported
	<i>Continuation and Maintenance Phase</i>	39.26%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				

<i>Blood Glucose Testing (Total)</i>		62.82%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		38.56%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		37.97%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening (Total)</i>		20.09%	R	R	Reported
<i>Follow-Up on Positive Screen (Total)</i>		65.70%	R	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of PHQ-9-Total (Total)</i>		13.75%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Follow-Up PHQ-9 (Total)</i>		48.91%	R	R	Reported
<i>Depression Remission (Total)</i>		16.72%	R	R	Reported
<i>Depression Response (Total)</i>		23.76%	R	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening (Total)</i>		0.33%	R	R	Reported
<i>Alcohol Counseling or Other Follow-Up Care (Total)</i>		1.27%	R	R	Reported
Adult Immunization Status (AIS-E)					
<i>Influenza (19-65)</i>		19.03%	R	R	Reported
<i>Influenza (66+)</i>		46.83%	R	R	Reported
<i>Influenza (Total)</i>		20.91%	R	R	Reported
<i>Td/Tdap (19-65)</i>		50.47%	R	R	Reported
<i>Td/Tdap (66+)</i>		43.30%	R	R	Reported
<i>Td/Tdap (Total)</i>		49.98%	R	R	Reported
<i>Zoster (50-65)</i>		14.12%	R	R	Reported
<i>Zoster (66+)</i>		31.81%	R	R	Reported
<i>Zoster (Total)</i>		18.36%	R	R	Reported
<i>Pneumococcal (66+)</i>		67.28%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Influenza</i>		38.09%	R	R	Reported
<i>Tdap</i>		66.73%	R	R	Reported
<i>Combination</i>		33.23%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Depression Screening</i>		41.38%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		48.33%	R	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Depression Screening</i>		27.42%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		58.70%	R	R	Reported
Social Need Screening and Intervention (SNS-E)					
<i>Food Screening (Total)</i>		0.00%	R	R	Reported
<i>Food Intervention (Total)</i>			NA	R	Reported
<i>Housing Screening (Total)</i>		0.00%	R	R	Reported
<i>Housing Intervention (Total)</i>			NA	R	Reported
<i>Transportation Screening (Total)</i>		0.00%	R	R	Reported
<i>Transportation Intervention (Total)</i>			NA	R	Reported